DE69615984D1 - Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen - Google Patents

Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen

Info

Publication number
DE69615984D1
DE69615984D1 DE69615984T DE69615984T DE69615984D1 DE 69615984 D1 DE69615984 D1 DE 69615984D1 DE 69615984 T DE69615984 T DE 69615984T DE 69615984 T DE69615984 T DE 69615984T DE 69615984 D1 DE69615984 D1 DE 69615984D1
Authority
DE
Germany
Prior art keywords
ursolic acid
medicament
manufacture
metastases
suppressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69615984T
Other languages
English (en)
Other versions
DE69615984T2 (de
Inventor
Hiromichi Ishikawa
Satoshi Nishimuro
Tomoko Kojima
Mitsuru Hirota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JCR Pharmaceuticals Co Ltd
Original Assignee
JCR Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JCR Pharmaceuticals Co Ltd filed Critical JCR Pharmaceuticals Co Ltd
Application granted granted Critical
Publication of DE69615984D1 publication Critical patent/DE69615984D1/de
Publication of DE69615984T2 publication Critical patent/DE69615984T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69615984T 1995-11-16 1996-11-15 Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen Expired - Lifetime DE69615984T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7323710A JP3041232B2 (ja) 1995-11-16 1995-11-16 癌転移抑制剤

Publications (2)

Publication Number Publication Date
DE69615984D1 true DE69615984D1 (de) 2001-11-22
DE69615984T2 DE69615984T2 (de) 2002-07-04

Family

ID=18157744

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69615984T Expired - Lifetime DE69615984T2 (de) 1995-11-16 1996-11-15 Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen

Country Status (7)

Country Link
US (1) US5985924A (de)
EP (1) EP0774255B1 (de)
JP (1) JP3041232B2 (de)
KR (1) KR100424503B1 (de)
CN (1) CN1073843C (de)
AT (1) ATE206914T1 (de)
DE (1) DE69615984T2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775686B1 (fr) * 1998-03-09 2006-07-28 Pascal Commenil Exploitation industrielle et commerciale des lipides cuticulaires de la baie de raisin en pharmacologie et cosmetologie
DE60102402T2 (de) * 2000-02-10 2005-03-10 Loders Croklaan B.V. Fettmischungen mit Kristallmodifikatoren
AU2002224595A1 (en) * 2000-07-31 2002-02-13 The Nisshin Oil Mills, Ltd. Antitumor agents
AU2001283038A1 (en) * 2000-07-31 2002-02-13 University Of Virginia Patent Foundation Inhibitors of dna polymerase sigma
WO2002047702A1 (en) * 2000-12-15 2002-06-20 Naturalendo Tech Co., Ltd. Compositions for inducing secretion of insulin-like growth factor-1
US6979470B2 (en) * 2001-07-17 2005-12-27 Metaproteomics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US20040029906A1 (en) * 2001-07-31 2004-02-12 Michael Christman Inhibitors of dna polymerase sigma
CA2486704A1 (en) * 2002-05-24 2003-12-04 Greystone Medical Group, Inc. Anti-cancer formulation
CN1243538C (zh) * 2002-11-21 2006-03-01 武汉利元亨药物技术有限公司 熊果酸豆磷脂纳米粒冻干粉针及制备方法
WO2005034958A1 (en) 2003-10-10 2005-04-21 Sk Chemicals, Co., Ltd. Triterpene compounds which are effective on improvement of brain function
JP4810642B2 (ja) * 2004-11-30 2011-11-09 秋田県 癌転移抑制用トリテルペン誘導体及び該トリテルペン誘導体を用いた癌転移抑制用組成物
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
WO2014022772A1 (en) 2012-08-03 2014-02-06 University Of Iowa Research Foundation Tomatidine, analogs thereof, compositions comprising same, and uses for same
AU2011255495A1 (en) * 2010-05-20 2012-12-06 The United States Of America, As Represented By The Secretary Of The Department Of Veterans Affairs Methods for inhibiting muscle atrophy
CA2838275C (en) 2011-06-06 2021-08-10 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
US10688158B2 (en) * 2012-07-05 2020-06-23 Nutramax Laboratories, Inc. Compositions comprising sulforaphane or a sulforaphane precursor and a milk thistle extract or powder
JP6211380B2 (ja) * 2012-10-17 2017-10-11 丸善製薬株式会社 Ｔｉｅ２活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤
KR102155125B1 (ko) * 2015-07-17 2020-09-11 경희대학교 산학협력단 악성 중피종 예방 또는 치료용 조성물
CN105534991A (zh) * 2015-12-24 2016-05-04 上海交通大学医学院 五环三萜类化合物在制备usp7抑制剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE707409A (de) * 1967-12-01 1968-04-16
JPS6439973A (en) * 1987-08-06 1989-02-10 Taiyo Kagaku Kk Drink composition
JPH03287530A (ja) * 1990-03-31 1991-12-18 Snow Brand Milk Prod Co Ltd 免疫抑制剤
US5519008A (en) * 1992-09-10 1996-05-21 Glycomed Incorporated Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin)
JPH0748250A (ja) * 1993-06-04 1995-02-21 Sekisui Chem Co Ltd 眠気防止用テープ
US5643884A (en) * 1993-08-09 1997-07-01 Glycomed Incorporated Lupane triterpenoid derivatives

Also Published As

Publication number Publication date
CN1073843C (zh) 2001-10-31
CN1157716A (zh) 1997-08-27
KR970025615A (ko) 1997-06-24
US5985924A (en) 1999-11-16
JPH09143076A (ja) 1997-06-03
JP3041232B2 (ja) 2000-05-15
ATE206914T1 (de) 2001-11-15
EP0774255B1 (de) 2001-10-17
DE69615984T2 (de) 2002-07-04
EP0774255A1 (de) 1997-05-21
KR100424503B1 (ko) 2004-06-04

Similar Documents

Publication Publication Date Title
DE69615984D1 (de) Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
KR900700089A (ko) 전신성 피부 투과적 투여를 위한 약학적 조성물
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69331409T2 (de) Oral 1alpha-hydroxyprevitamin d
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
HUP0100437A2 (hu) Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására
DE3855113D1 (de) Verwendung von Buspiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung der Alkoholsucht
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE68912459D1 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.
ATE99172T1 (de) Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
DE69522511T2 (de) Spirooxathiolan-quinuclidin-Derivat zur Behandlung von Xerostomie
DE69428325D1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung der Angiogenese und angiogene Krankheiten
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
DE3888340D1 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
DE68917937D1 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.
EP0647616A4 (de) Zink-tranexamat derivat.
ES2052000T3 (es) Procedimiento para preparar composiciones farmaceuticas que contienen pentamidina.
KR910015300A (ko) 부스피론 : 수면 무호흡증의 치료용도
ATE181503T1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution
KR880004810A (ko) 소화성 궤양 치료제
DE68910010D1 (de) Verwendung von Dapiprazol zur Herstellung eines Arzneimittels zur Verhinderung des Toleranzentwicklung bei der analgetischen Behandlung mit Morphin.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition